ArcticZymes Technologies ASA: Notice of Annual General Meeting 26
The annual general meeting ("AGM") for ArcticZymes Technologies ASA will be held on Thursday 28. May 2026 at 12.00 CET. The meeting will be held as a physical meeting, with an option for shareholders to participate digitally.
ArcticZymes' M-SAN HQ Sets New Standard for Measles Virus Purification with Unmatched DNA Clearance & High Recovery Rates
Tromsø, Norway – November 21, 2024 – ArcticZymes Technologies ASA (OSE: AZT), is proud to highlight the exceptional performance of our M-SAN HQ nuclease in the purification of recombinant measles viruses (MV), as detailed in a recent publication in the Journal of Chromatography A.
ArcticZymes Technologies Announces Commercial Strategic Transformation and Q3 2024 Financial Results
Tromsø, Norway, November 6th, 2024 – ArcticZymes Technologies (OSE: AZT) reported revenues of NOK 24.1 million and an EBITDA of NOK -2.3 million for the third quarter of 2024.
ArcticZymes Highlights Industry-Leading Success at ESGCT 2024
ArcticZymes Technologies ASA (OSE: AZT), a global leader in enzyme innovation for bioprocessing, is excited to unveil breakthrough developments presented at the prestigious European Society of Gene and Cell Therapy (ESGCT) 2024 conference
ArcticZymes Leverages Rising Interest in Salt-Active Nucleases with New Whitepaper on Advancing Viral Vector Manufacturing
ArcticZymes Leverages Rising Interest in Salt-Active Nucleases with New Whitepaper on Advancing Viral Vector Manufacturing